{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:31Z","timestamp":1790345011770,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ero.2026.100216","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:17:22Z","timestamp":1783923442000},"page":"100216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From drug mechanism\u2013based to driver-guided therapy: targeting disease drivers in psoriatic arthritis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-6759","authenticated-orcid":false,"given":"Thorben","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ero.2026.100216_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0002","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(24)00268-6","article-title":"Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease","volume":"7","author":"Ciccia","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"17","key":"10.1016\/j.ero.2026.100216_bib0003","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1080\/14656566.2025.2601050","article-title":"Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment","volume":"26","author":"Arraf","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.ero.2026.100216_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3899\/jrheum.2025-0518","article-title":"Incidence and predictors of secondary failure to biologic therapy in patients with psoriatic arthritis","volume":"53","author":"Kharouf","year":"2026","journal-title":"J Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100216_bib0005","article-title":"Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis","volume":"2","author":"Cagnotto","year":"2025","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13075-025-03518-7","article-title":"Burden and determinants of multi-b\/tsDMARD failure in psoriatic arthritis","volume":"27","author":"Haberman","year":"2025","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci Rep."},{"issue":"11","key":"10.1016\/j.ero.2026.100216_bib0008","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","article-title":"Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results","volume":"80","author":"Smolen","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ero.2026.100216_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102721","article-title":"If it\u2019s a target, it\u2019s a pan-cancer target: tissue is not the issue","volume":"125","author":"Adashek","year":"2024","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.ero.2026.100216_bib0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard-2024-226150","article-title":"Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium","volume":"84","author":"Karmacharya","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-025-03670-0","article-title":"Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Na\u00efve patients in two phase 3 clinical trials","volume":"28","author":"Gossec","year":"2025","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"10.1016\/j.ero.2026.100216_bib0012","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41584-023-01016-1","article-title":"Imaging in inflammatory arthritis: progress towards precision medicine","volume":"19","author":"Minopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2026.100216_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103839","article-title":"Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease","volume":"24","author":"Witte","year":"2025","journal-title":"Autoimmun Rev."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.10.002","article-title":"EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis","volume":"85","author":"Marzo-Ortega","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ero.2026.100216_bib0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41584-025-01329-3","article-title":"Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative","volume":"22","author":"Proft","year":"2026","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005785","article-title":"Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis","volume":"11","author":"Zabotti","year":"2025","journal-title":"RMD Open."},{"key":"10.1016\/j.ero.2026.100216_bib0017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ard.2025.05.492","article-title":"POS0104: whole-body MRI (WB-MRI) to assess response to adalimumab, guselkumab, and ustekinumab in psoriatic arthritis (PsA): imaging results from the TIGERS study","volume":"84","author":"Chabot","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ero.2026.100216_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004294","article-title":"Anatomical pattern of entheseal and synovial fibroblast activation in patients with psoriasis and its risk of developing psoriatic arthritis","volume":"10","author":"Corte","year":"2024","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006567","article-title":"Increased synovial and entheseal fibroblast activation detected by (68)Ga-FAPI-PET\/CT is associated with the development of psoriatic arthritis in psoriasis patients with arthralgia","volume":"12","author":"Corte","year":"2026","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ero.2026.100216_bib0020","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2026","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2026.100216_bib0022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jdv.70247","article-title":"Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis","volume":"40","author":"Morrow","year":"2026","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0023","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1186\/s12967-025-07130-w","article-title":"Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: evidence from a real-world cohort","volume":"23","author":"Xu","year":"2025","journal-title":"J Transl Med."},{"key":"10.1016\/j.ero.2026.100216_bib0024","article-title":"Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial","volume":"15","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ero.2026.100216_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ero.2026.100216_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964274","article-title":"Combined\u2014whole blood and skin fibroblasts\u2014transcriptomic analysis in psoriatic arthritis reveals molecular signatures of activity, resistance and early response to treatment","volume":"13","author":"Grivas","year":"2022","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.ero.2026.100216_bib0027","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3899\/jrheum.2024-0396","article-title":"Candidate biomarkers for response to treatment in psoriatic disease","volume":"51","author":"Offenheim","year":"2024","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100216_bib0028","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0029","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ard.2025.10.011","article-title":"CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study","volume":"85","author":"Eder","year":"2026","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ero.2026.100216_bib0030","article-title":"Combined single cell transcriptome and surface epitope profiling identifies potential biomarkers of psoriatic arthritis and facilitates diagnosis via machine learning","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0031","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(25)00348-0","article-title":"The path to interception in psoriatic disease: from conceptual clarity to clinical translation","volume":"8","author":"McGagh","year":"2026","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100216_bib0032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat Rev Rheumatol."}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:29:42Z","timestamp":1790342982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3050708126001151"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.100216","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From drug mechanism\u2013based to driver-guided therapy: targeting disease drivers in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.100216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100216"}}